# The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

> **NCT01451333** · PHASE3 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 32 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** Efavirenz
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT01451333
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-10
- **Final completion:** 2013-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451333, "The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01451333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*